LEWIS JOEL 4/A

What Happened
Joel Lewis, President, CEO and a director of Galectin Therapeutics, received a grant of 91,000 derivative awards (reported as common stock options) on January 16, 2026. The filing shows the acquisition as a grant (transaction code A) with a reported price of $0.00 for reporting purposes; this is an equity award rather than an open-market purchase or sale.

Key Details

• Transaction date: January 16, 2026; Form 4 amendment filed January 22, 2026.
• Transaction type: Award/Grant of derivative securities (options) — 91,000 shares reported. Reported price: $0.00 (reflects award reporting, not a cash purchase).
• Plan: Issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan (F1).
• Vesting: Options vest 25% on each of June 30, 2026; December 31, 2026; June 30, 2027; and December 31, 2027 (F2).
• Amendment: This filing corrects the number of options reported in the original Form 4 (F3).
• Shares owned after transaction: Not specified in the provided summary of the filing.

Context

• This was a compensation grant (award) to an executive — common for senior management and not the same as a market purchase or sale. It does not indicate an immediate sale of shares or an option exercise.
• The award vests over four installments; until vested and exercised (if these are options), the awards are not freely tradable common shares.
• The filing is an amendment to correct the originally reported option amount; the amendment itself does not explain motivations and should be viewed as a corrective disclosure rather than a new trade signal.